Eckert & Ziegler Hosts Successful 3rd Boston Radionuclide Theranostics Forum to Shape the Future of Precision Oncology

Eckert & Ziegler Hosts Successful 3rd Boston Radionuclide Theranostics Forum to Shape the Future of Precision Oncology

(IN BRIEF) Eckert & Ziegler successfully hosted the 3rd annual Boston Radionuclide Theranostics Forum, bringing together industry leaders to discuss radionuclide theranostics’ role in transforming precision oncology. The event featured expert presentations on advancements in radiopharmaceuticals, clinical development challenges, and industry deals. With over 100 decision-makers in attendance, the forum reinforced Eckert & Ziegler’s commitment to advancing innovation and patient access to therapies. The event’s success underscores its status as a vital platform in the radiopharmaceutical industry, with the next forum scheduled for May 28, 2026.

(PRESS RELEASE) BERLIN, 30-May-2025 — /EuropaWire/ — Eckert & Ziegler has successfully hosted the third annual Boston Radionuclide Theranostics Forum, reinforcing its leadership in the radiopharmaceutical industry. This year’s forum, held on May 29, 2025, brought together approximately 100 key decision-makers, experts, partners, and industry leaders to discuss the transformative potential of radionuclides in precision oncology.

The event, which built on the success of its previous editions, centered on whether radionuclide theranostics is reaching maturity as a transformative force in precision oncology. Discussions delved into the latest advancements in radiopharmaceuticals, as well as key issues around supply chains, clinical development challenges, and deal-making within the radiotherapeutic field. The event also offered insights through panel discussions and expert-led presentations, providing a comprehensive view of the current landscape in radiotheranostics.

Dr. Harald Hasselmann, CEO of Eckert & Ziegler SE, expressed, “The rapid advancements and growth in the radiopharmaceutical sector are clear. Hosting the third edition of the Boston Radionuclide Theranostics Forum underscores our commitment to driving progress in precision oncology. The valuable discussions and collaborations at this event have the potential to fast-track innovation and broaden patient access to life-saving therapies.”

The Boston Radionuclide Theranostics Forum, organized by Eckert & Ziegler, was sponsored by Solomon Partners, hosted by Morrison Foerster, and supported by the German American Business Council of Boston. This event has become a premier fixture in the nuclear medicine calendar. With a half-day agenda, over a dozen international experts contributed insights from clinical practice, research, and industry innovation. The event was a hub for networking, strategic discussions, and collaboration among the global radiopharmaceutical community.

By invitation only, the forum saw full attendance, reflecting the high demand and commitment from professionals in the radiopharmaceutical field. Eckert & Ziegler has already set the date for the next edition, which will take place on May 28, 2026, further cementing the forum’s role in advancing precision oncology.

About Eckert & Ziegler
Eckert & Ziegler SE, with more than 1,000 employees, is a leading specialist in isotope-related components for nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.

Contributing to saving lives

Media Contact:

Jan Schöpflin, Marketing
jan.schoepflin@ezag.com
Tel.: +49 (0) 30 / 94 10 84-252
www.ezag.com

SOURCE: Eckert & Ziegler SE